Full Press Release Details
Cellectar to Release
Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Financial Results for Third Quarter 2023 and Provides a Corporate Update
Conference Call scheduled
for today at 8:30 am Eastern Time
PARK, N.J., Nov. 2, 2023 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical
company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that
top-line data from the pivotal trial in Waldenstrom's macroglobulinemia (WM) will be released during the JP Morgan Healthcare conference
the week of January 8, 2024.
Recent Corporate Highlights
continue to collect and evaluate patient data from our pivotal trial and expect to announce top-line data the week of January 8,
2024. We view this data announcement as a potentially transformational event for Cellectar and as such merits optimal market and
industry awareness, which the JP Morgan conference provides. As we prepare to announce trial data, we continue to work with the
FDA and progress the NDA submission while advancing our commercialization readiness," said James Caruso, president and CEO of Cellectar.
"With the recent financing providing up to $102.9 million in funding, we believe the company is well positioned for success with
a clearly differentiated lead asset poised to establish a new standard of care for patients with relapsed or refractory WM."
Preliminary Third Quarter 2023 Financial Highlights
Conference Call & Webcast Details
management will host a conference call for investors today, November 2, 2023, beginning at 8:30 am Eastern Time to discuss these
results and answer questions. Stockholders and other interested parties may participate in the conference call by dialing 1-888-886-7786
(in the U.S.) or 1-416-764-8658 (outside the U.S.). The call will be available via webcast by clicking HERE or on the Events
page of the company's website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical
biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and
through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug
Conjugate (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy
and better safety as a result of fewer off-target effects.
The company's product pipeline includes
lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical
PDC chemotherapeutic programs and multiple partnered PDC assets.
more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking
and following us on the company's social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement Disclaimer
This news release contains forward-looking statements.
You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations
as to such future outcomes including our expectations regarding the WM CLOVER-WaM pivotal trial. Drug discovery and development involve
a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability
to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract
and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient
enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan
drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators'
ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and
third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports
filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2022, and our Form 10-Q
for the quarter ended June 30, 2023. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation
to update any such forward-looking statements.